Effects of Genetic Variations in the Response to Brazil Nut Supplementation

Genetic Variants in Selenoprotein Genes and Gender Influence Biomarkers of Se Status in Response to Brazil Nut Supplementation in Healthy Brazilians

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03111355

Acronym

SUBRANUT

Enrollment

129

Registered

2017-04-12

Start date

2013-03-01

Completion date

2016-04-19

Last updated

2018-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dietary Supplements

Keywords

nuts, micronutrients, nutrigenomics, nutrigenetics

Brief summary

This study investigates the effect of genetic variations after supplementation with Brazil nuts in healthy Brazilians. Briefly, all the participants will consume one nut a day for 2 months and will stop the intake for more 2 months. Five blood sampling collection will be performed in one month interval, starting at baseline and ending at 2 months without intervention.

Detailed description

Brazil nuts are the richest source of selenium in nature, a micronutrient that has essential functions in human physiology. Selenium status can be measured by the quantification of biomarkers in the blood. Previous studies have shown that genetic polymorphisms can affect Se status and modulate risk for chronic diseases. In this study, five biomarkers will be quantified in the blood, before and after supplementation with Brazil nuts. The genetic variants will be used to stratify the biomarkers and multivariate linear regressions will be used to explore the influence of the polymorphisms on concentrations of the biomarkers .

Interventions

DIETARY_SUPPLEMENTBrazil nut

one nut a day for 2 months, no intervention for 2 months

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

BASIC_SCIENCE

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

20 Years to 60 Years

Healthy volunteers

Yes

Inclusion criteria

* age between 20 and 60 years; not taking vitamin and minerals supplements, not taking antiinflammatory, not having chronic diseases

Exclusion criteria

* athletes, excessive alcohol consumption, being obese, having cancer, cardiovascular disease, diabetes and hypo or hyperthyroidism

Design outcomes

Primary

Measure	Time frame	Description
change in Plasma Se concentrations	4 weeks	measured by ICP-MS (ug/L)
change in Plasma Glutathione Peroxidase 3 activity	4 weeks	measured by kinetic assay in a spectrometer (U/L)
change in Plasma Selenoprotein P concentrations	4 weeks	measured by ELISA (mg/dL)
change in Erythrocyte Se concentrations	4 weeks	measured by ICP-MS (ug/L)
change in Erythrocyte Glutathione Peroxidase 1 activity	4 weeks	measured by kinetic assay in an automatic spectrometer (U/gHb)

Secondary

Measure	Time frame	Description
change in total cholesterol concentration in serum	4 weeks	measured in an automatic spectrometer (mg/dL)
change in Plasma MDA concentrations (malondialdehyde)	4 weeks	measured in an automatic spectrometer (mg/dL)
change in tryglicerides concentration in serum	4 weeks	measured in an automatic spectrometer (mg/dL)
change in HDL concentration in serum	4 weeks	measured in an automatic spectrometer (mg/dL)
change in LDL concentration in serum	4 weeks	measured in an automatic spectrometer (mg/dL)
change in protein-c reactive concentration in serum	4 weeks	measured in an automatic spectrometer (mg/dL)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026